Docetaxel 60 mg/m2

DRUG2 trials

Sponsors

AstraZeneca, Memorial Sloan Kettering Cancer Center

Conditions

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IVProstate Cancer

Phase 2

Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.

CompletedNCT01750281

AstraZenecaLocally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV

Start: 2012-12-18End: 2022-10-31Updated: 2023-10-24

Phase 3

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Active, not recruitingNCT03574571

Memorial Sloan Kettering Cancer CenterProstate Cancer

Start: 2018-06-19End: 2027-04-01Updated: 2026-02-27

Related Papers

AlphaBet: Combination of Radium-223 and [177Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)

Frontiers in Medicine2022-11-1840 citations

A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.

Journal of Clinical Oncology2021-05-206 citations

A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.

Journal of Clinical Oncology2020-05-201 citations

Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial

European Journal of Cancer2019-05-1154 citations

A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.

Journal of Clinical Oncology2019-03-011 citations

Abstract 4760: Joint modeling of longitudinal tumor dynamics and survival in non-small cell lung cancer (NSCLC) patients

Cancer Research2018-07-018 citations

SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer.

2017-12-0122 citations

A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors

BMC Cancer2017-03-0620 citations